OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a report released on Tuesday. The firm issued a sell rating on the stock.

Separately, Needham & Company LLC restated a “buy” rating and issued a $4.25 target price on shares of OncoCyte in a research report on Wednesday, November 13th.

OncoCyte Trading Down 3.8 %

Shares of OncoCyte stock opened at $2.44 on Tuesday. OncoCyte has a one year low of $2.00 and a one year high of $4.19. The business’s 50 day moving average price is $2.94 and its 200 day moving average price is $2.97.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. The company had revenue of $0.12 million for the quarter. During the same quarter last year, the firm posted ($0.57) EPS.

Insider Buying and Selling at OncoCyte

In other news, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was acquired at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the purchase, the insider now owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. This represents a 26.69 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Andrea S. James acquired 33,670 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was purchased at an average cost of $2.97 per share, with a total value of $99,999.90. Following the completion of the purchase, the chief financial officer now directly owns 33,670 shares of the company’s stock, valued at approximately $99,999.90. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.58% of the company’s stock.

Institutional Investors Weigh In On OncoCyte

A hedge fund recently raised its stake in OncoCyte stock. Geode Capital Management LLC increased its stake in shares of OncoCyte Co. (NASDAQ:OCX) by 12.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,980 shares of the company’s stock after purchasing an additional 11,289 shares during the quarter. Geode Capital Management LLC owned 0.62% of OncoCyte worth $296,000 at the end of the most recent quarter. 55.35% of the stock is currently owned by institutional investors.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.